Alligator Bioscience publishes financial calendar for 2026

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), hereby publishes its financial calendar for 2026:

Deadline for Alligator Bioscience’s shareholders to submit resolutions to be considered by the Annual General Meeting	31 January 2026
Year-end report 2025	12 February 2026
Annual report 2025	March 2026
Interim report Q1 2026	5 May 2026
Annual General Meeting	6 May 2026
Interim report H1 2026	27 August 2026
Interim report Q3 2026	22 October 2026
Year-end report 2026	11 February 2027

About Alligator Bioscience

Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company’s lead drug candidate mitazalimab is currently ready for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1.

Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

Categorized as